Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1196 results
December 2018
-
Media ReleaseNovartis investigational BYL719 (alpelisib) plus fulvestrant consistently improved PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer in new SOLAR-1 analysesBYL719 plus fulvestrant meaningfully prolonged PFS vs fulvestrant alone in patients with PIK3CA mutated HR+/HER2- advanced breast cancer after progression on an aromatase inhibitor…
-
Media ReleaseNovartis advances ligelizumab (QGE031) in urticaria to Phase III on basis of strong Phase II head-to-head dataPEARL 1 and PEARL 2, the largest pivotal trials to date in chronic spontaneous urticaria (CSU), will enroll more than 2,000 CSU patients[1],[2] Ligelizumab (QGE031), a monoclonal antibody…
-
Media ReleaseNovartis announces FDA filing acceptance and Priority Review of AVXS-101, a one-time treatment designed to address the genetic root cause of SMA Type 1The AVXS-101, now known as ZOLGENSMA® (onasemnogene abeparvovec-xxxx)[1], filing is supported by data from the START trial which demonstrated a dramatic increase in survival and transformative…
-
Media ReleaseReal-world data show Novartis drug Revolade® improves outcomes for ITP patients compared to other second-line therapiesRevolade (eltrombopag) showed lower rate of bleeding-related episodes and similar rate of thrombotic events vs. romiplostim, rituximab and splenectomy, in a retrospective analysis of US electronic…
-
Media ReleaseNovartis announces longer-term analyses from pivotal Kymriah® trials that showed durable responses are maintained in patients with advanced blood cancersIn the updated analysis from ELIANA, Kymriah demonstrated an 82% remission rate within 3 months in pediatric patients with r/r ALL; relapse-free survival was 62% at 24 months, with median duration…
-
Media ReleaseNovartis announces new crizanlizumab (SEG101) data analysis in sickle cell disease, and investment in SENTRY clinical programNew post-hoc analysis of SUSTAIN study, presented at ASH 2018, highlights results among patients who were treated per protocol compared with all randomized patientsCrizanlizumab, a monthly infusion…
November 2018
-
Media ReleaseNovartis announces EU approval of Gilenya® for children and adolescents with MS, making it the first and only oral disease-modifying treatment for these patients in EuropeApproval based on landmark PARADIGMS study showing Gilenya (fingolimod) significantly reduced relapse rates by 82% vs interferon beta-1a; additionally, 85.7% of Gilenya patients were relapse-free…
-
Media ReleaseSandoz receives eighth European Commission approval for a biosimilar with Ziextenzo® (pegfilgrastim)Biosimilar Ziextenzo® (pegfilgrastim), a long-acting version of supportive oncology medicine filgrastim, is now approved for use in all reference medicine indications [1] Ziextenzo is indicated…
-
Media ReleaseAlcon to highlight its vision, strategy and benefits as a standalone company to investors and analysts in New York and LondonAlcon is the global leader in the highly attractive and growing $23 billion eye care devices market Market leading development capabilities and innovation investments Clearly defined near and…
-
Media ReleaseNovartis announces landmark EU approval for one-time gene therapy Luxturna® to restore vision in people with rare inherited retinal diseaseLuxturna* (voretigene neparvovec) is the first gene therapy to treat an inherited retinal disease, indicated for children and adults with vision loss caused by mutations in both copies of the RPE65…
-
Media ReleaseNovartis rises to second place in 2018 Access to Medicine IndexCompany leads the industry in access-to-medicine management thanks to long- term commitment, as well as ongoing innovation in access to healthcare Novartis moves up one position from number 3 in…
-
Media ReleaseSandoz and Pear Therapeutics announce launch of reSET® for treatment of patients with Substance Use DisorderreSET® is the first and only FDA-authorized prescription digital therapeutic for Substance Use Disorder (SUD) Adding reSET to outpatient therapy significantly improved abstinence in substances of…
Pagination
- ‹ Previous page
- 1
- …
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- …
- 100
- › Next page